Venrock Adviser, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001615982

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2024 · 38 positions · Total reported value $1.91B · Top-10 concentration 65.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 41.0% · 6 new · 5 cut · 5 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2024 13F filing, Venrock Adviser, LLC disclosed 38 equity positions with a combined reported value of $1.91B. The filing implies a focused portfolio: its ten largest positions account for 65.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were APGE ($498.90M), OCUL ($111.03M), ELVN ($102.83M). By sector, the heaviest allocations are Health Care 57.5%, Materials 0.3%. Versus the prior quarter, allocation shifted toward Other (+2.3pp) and away from Health Care (-2.6pp).

Versus the prior quarter, Venrock Adviser, LLC opened 6 new positions, trimmed 5 and fully exited 5, a turnover rate of 41.0% of positions. The portfolio's overlap with the prior quarter was 87% of names.

The largest new positions opened in Q3 2024 were ORKA ($75.63M), ARTV ($24.87M), TIL ($2.23M).

Of the 5 positions fully exited versus the prior quarter, the largest were ABIO ($3.32M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • ORKA ORUKA THERAPEUTICS INC · $75.63M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $24.87M
  • TIL INSTIL BIO INC · $2.23M
  • TENX TENAX THERAPEUTICS INC · $720.83K

Fully Exited (vs previous quarter)

  • ABIO ARCA BIOPHARMA INC · prev qtr: $3.32M

Insider Transactions (Form 4)

Latest Venrock Adviser, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Venrock Adviser, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 34 US equity positions with a combined value of $2.06B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-79382 (status: Approved), registered 2014-04-09
  • Regulatory AUM (Form ADV): $4.50B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 34 positions · $2.06B reported value (Q3 2026)
  • Top 10 holdings = 71.0% of reported value
  • Largest position: ORKA (ORUKA THERAPEUTICS INC) at 16.8%
  • Average position size: $60.54M

Sector Tilt

  • Health Care 99.6%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 6 new, 6 added, 5 reduced, 5 exited
  • 17 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 57.5%
Materials 0.3%
Other 42.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 8.49M $498.90M 26.13%
26.13%
Hold
2 12.76M $111.03M 5.82%
5.82%
Hold
3 4.03M $102.83M 5.39%
5.39%
Hold
4 3.88M $88.33M 4.63%
4.63%
Hold
5 9.82M $83.51M 4.37%
4.37%
Add
6 2.69M $78.98M 4.14%
4.14%
Hold
7 2.17M $78.09M 4.09%
4.09%
Hold
8 3.09M $75.63M 3.96%
3.96%
New
9 6.25M $72.37M 3.79%
3.79%
Hold
10 3.40M $62.89M 3.29%
3.29%
Hold
11 5.68M $61.39M 3.21%
3.21%
Hold
12 1.74M $47.76M 2.50%
2.50%
Reduce
13 4.40M $47.56M 2.49%
2.49%
Hold
14 907.96K $45.36M 2.38%
2.38%
Reduce
15 4.39M $45.04M 2.36%
2.36%
Hold
16 16.22M $44.27M 2.32%
2.32%
Hold
17 706.13K $40.63M 2.13%
2.13%
Hold
18 3.46M $38.08M 1.99%
1.99%
Reduce
19 3.41M $28.44M 1.49%
1.49%
Hold
20 5.56M $27.67M 1.45%
1.45%
Hold
21 1.00M $26.69M 1.40%
1.40%
Reduce
22 1.61M $24.87M 1.30%
1.30%
New
23 3.57M $23.53M 1.23%
1.23%
Add
24 1.38M $23.10M 1.21%
1.21%
Hold
25 11.33M $21.41M 1.12%
1.12%
Hold
26 9.00M $18.09M 0.95%
0.95%
Hold
27 1.35M $15.50M 0.81%
0.81%
Hold
28 3.42M $11.43M 0.60%
0.60%
Hold
29 454.45K $11.19M 0.59%
0.59%
Reduce
30 1.47M $10.30M 0.54%
0.54%
Hold
31 5.39M $9.22M 0.48%
0.48%
Hold
32 2.02M $8.21M 0.43%
0.43%
Reduce
33 750.00K $7.51M 0.39%
0.39%
Hold
34 1.56M $7.38M 0.39%
0.39%
Hold
35 987.26K $6.08M 0.32%
0.32%
Add
36 1.56M $3.00M 0.16%
0.16%
Hold
37 33.18K $2.23M 0.12%
0.12%
New
38 208.33K $720.83K 0.04%
0.04%
New

FAQ

What did Venrock Adviser, LLC buy in 2024-Q3?

In its 2024-Q3 13F filing, Venrock Adviser, LLC reported 38 equity positions worth $1.91B in aggregate; its largest disclosed positions were APGE ($498.90M), OCUL ($111.03M), ELVN ($102.83M).

How large is Venrock Adviser, LLC's portfolio?

Venrock Adviser, LLC reported $1.91B of long equity holdings across 38 positions as of 2024-Q3. Top-10 holdings account for 65.6% of reported value.

What is Venrock Adviser, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/venrock-adviser/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →